hotspot -WSS

hotspot

author：leisure time 2025-09-27 09:54:10 - browse：111

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Why health care costs have stayed mostly flat since 2010

focus

WSS

Keeping primary care docs in field isn't impossible, says AAFP CEO

The inclusion problem at the heart of rehabilitation research

Immunocompromised patients offer clues on chronic Covid

Why health care costs have stayed mostly flat since 2010

FDA sets aggressive timeline for overhauling inspection procedures

Medicare drug price lawsuits could be good politics for Biden

knowledge

hotspot

focus

Dobbs anniversary: the lost opportunity of abortion as health care

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

New air purifier tech could be key to improving indoor air quality

Why health records don't always know when patients are dead

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

The high cost of giving birth even with insurance

Medicare Advantage beneficiaries sue Humana over algorithm use

New air purifier tech could be key to improving indoor air quality

CRISPR gene editing developments we’re watching in 2024

focus

Prime Medicine, Myeloid Therapeutics clash over genome

The inclusion problem at the heart of rehabilitation research

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Future doctors need a strong humanities education

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Why health records don't always know when patients are dead

knowledge

leisure time

focus

explore